
|Articles|May 4, 2021
Isolation of Tumor-Infiltrating Lymphocytes from Dissociated Tumor Cells
Author(s)BioIVT
Tumor-infiltrating lymphocytes may hold the key to treating solid tumors with cell therapies, and BioIVT’s DTC product line is a great source for TILs. In this white paper, you’ll read about defining what TILs are, their potential therapeutic applications, the characterization of BioIVT’s current donor pool by TIL content and the frequency of TILs by tumor tissue type.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
CDC Revises Childhood Immunization Schedule, Shifting Demand Dynamics
2
New AI Oncology Alliance Highlights Industry Push for Scalable Genomics
3
Industry Outlook 2026: Biopharma Braces for Economic Upheaval While Eyeing AI-Driven Transformation (Part 1)
4
What Are the Benefits of Single-Use in CGT Manufacturing?
5